IP Library Granted Patent US 12,208,077
Granted Patent B2
US 12,208,077 · App. 17/714,723 · Granted Jan 28, 2025

Synergistic composition for potentiating stabilized ATP

Inventors: Rajaram Samant (Thane West, IN); Rajendra Prasad Tongra (Jaipur, IN)
Assignee: CELAGENEX RESEARCH (INDIA) PVT. LTD.
A61K31/221A61K31/185A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,077
App. No.
17/714,723
Granted
Jan 28, 2025
Kind
B2
Abstract

The present invention disclosed herein relates to a synergistic composition for potentiating stabilized ATP. Particularly, the invention provides the synergistic composition for improving cellular energy in a subject in need thereof. More particularly, the invention relates to compositions comprising synergistic combination therapeutically active ALCAR and MgAT which are present in the weight ratio of 1:0.002 to 1:1, along with pharmaceutically acceptable excipients. Further, the present composition is useful for improving tiredness, fatigue, cognition, memory, increase mental alertness, concentration, endurance, boost energy levels and wakefulness. It also useful for treating depression, anxiety related symptoms.

Claims (13)

1. A synergistic composition for potentiating stabilized ATP, the synergistic composition comprising:

a therapeutically active exogenous blend consisting of acetyl L-carnitine and magnesium acetyl taurate; and

pharmaceutically acceptable excipients,

wherein the acetyl L-carnitine and the magnesium acetyl taurate are present in a weight ratio of 1:0.002 to 1:1.

2. The synergistic composition according to claim 1 , wherein the acetyl L-carnitine is present in a range of 50% to 99% by a total weight of the composition.

3. The synergistic composition according to claim 1 , wherein the magnesium acetyl taurate is present in a range of 1% to 50% by the total weight of the composition.

4. The synergistic composition according to claim 1 , wherein the pharmaceutically acceptable excipients are selected from a group consisting of a diluent present in a range of 1 to 30%, a binder present in a range of 0.1 to 25%, a lubricant present in a range of 0.1 to 10.0%, a glidant present in a range of 0.1 to 5.0%, an additive present in a range of 1 to 10%, a surfactant present in a range of 0.1 to 5.0%, a stabilizer present in a range of 0.1 to 5.0%, an antioxidant present in a range of 0.1 to 5.0%, and a plasticizer present in a range of 0.1 to 5.0%, by the total weight of the composition.

5. The synergistic composition according to claim 1 , wherein an administration of an effective unit dose of the synergistic composition improves ATP level by 65 to 575 folds over a normal cell control.

6. The synergistic composition according to claim 1 , wherein the acetyl L-carnitine and the magnesium acetyl taurate are present in a weight ratio of 1:0.005.

7. The synergistic composition according to claim 1 , wherein the acetyl L-carnitine and the magnesium acetyl taurate are present in a weight ratio of 1:0.01.

8. The synergistic composition according to claim 1 , wherein the acetyl L-carnitine and the magnesium acetyl taurate are present in a weight ratio of 1:1.

9. The synergistic composition according to claim 1 , wherein an oral administration of the synergistic composition improves tiredness, fatigue, weakness, cognition, memory, increase mental alertness, concentration, endurance, boost energy levels, wakefulness, conditions associated with ATP depletion, depression, or anxiety related symptoms.

10. The synergistic composition according to claim 5 , wherein the effective unit dose is formulated in a range of 10 mg to 1000 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: SAMANT, RAJARAM; TONGRA, RAJENDRA PRASAD, DR.
To: CELAGENEX RESEARCH (INDIA) PVT. LTD.
Reel/Frame 059562/0114 →
Priority Claims (1)
IN 202121016160 · Apr 6, 2021 · national
Continuity (1)
Related Publication 20220313644A1 · Oct 6, 2022
References Cited (25)
US 4415588A · Cavazza · 1983 [cited by applicant]
US 6245378B1 · Cavazza · 2001 [cited by applicant]
US 6602512B1 · Cavazza · 2003 [cited by applicant]
US 7060295B2 · Richardson · 2006 [cited by applicant]
US 8518455B2 · Pietro · 2013 [cited by applicant]
US 10130602B2 · Williams · 2018 [cited by applicant]
US 20050249713A1 · Gaetani · 2005 [cited by applicant]
JP 2001517085A · 2001 [cited by applicant]
WO 1998043499A2 · 1998 [cited by applicant]
WO 2000011968A1 · 2000 [cited by applicant]
James Heffley, “Magnesium taurate has considerable potential as a nutritional supplement, since both magnesium and taurine supplements improve a number of health conditions”, published online Jan. 27, 2006. the whole do… [cited by applicant]
Fassin, M., Danhier, P., & Ris, L. (2020). Effect of oral administration of Magnesium NAcetyltaurinate on synaptic plasticity in rodents. Magnesium Research, 33(4), 106-113. [cited by applicant]
Dane, H. (2017). Overcome Adrenal Fatigue: Regain Your Health & Energy. [cited by applicant]
Hosgorler, F., Koc, B., Kizildag, S., Canpolat, S., Argon, A., Karakilic, A., . . . & Uysal Harzadin, N. A. Z. A. N. (2020). Magnesium acetyl taurate prevents tissue damage and deterioration of prosocial behavior relate… [cited by applicant]
International Search Report dated Jul. 14, 2022 as received in application No. PCT/IN2022/050335. [cited by applicant]
Indian Examination Report dated Apr. 26, 2022 as received in application No. 202121016160. [cited by applicant]
Myhill, Booth, & Howard, 2009 Chronic fatigue syndrome and mitochondrial dysfunction. [cited by applicant]
Eur J Clin Pharmacol. 2000;56:49-55 Pharmacokinetics of intravenous ATP in cancer patients. [cited by applicant]
J Int Soc Sports Nutr. 2012; 9: 16 “Adenosine 5′-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans”. [cited by applicant]
Antonio Gnoni et al. molecules 2020, 25, 182 “Carnitine in Human Muscle Bioenergetics: Can Carnitine Supplementation Improve Physical Exercisec”. [cited by applicant]
Tomassini et al., “Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial” Journal of the Neurolo… [cited by applicant]
Am J Clin Nutr. Apr. 2011, 93(4):799-808 “Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study”. [cited by applicant]
Delhi psychiatry journal vol. 15 No. 1, Apr. 2012. [cited by applicant]
Dyn Med. 2006; 5: 1 “Oxygen cost of dynamic or isometric exercise relative to recruited muscle mass”. [cited by applicant]
Nutritional Outlook vol. 21 No. 7, Oct. 3, 2018. [cited by applicant]